| [1] |
Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249. DOI: 10.3322/caac.21660.
|
| [2] |
Joshi SS, Badgwell BD. Current treatment and recent progress in gastric cancer[J]. CA Cancer J Clin, 2021, 71(3): 264-279. DOI: 10.3322/caac.21657.
|
| [3] |
André T, Tougeron D, Piessen G, et al. Neoadjuvant nivolumab plus ipilimumab and adjuvant nivolumab in localized deficient mismatch repair/microsatellite instability-high gastric or esophagogastric junction adenocarcinoma: the GERCOR NEONIPIGA phase Ⅱ study[J]. J Clin Oncol, 2023, 41(2): 255-265. DOI: 10.1200/JCO.22.00686.
|
| [4] |
Pietrantonio F, Raimondi A, Lonardi S, et al. INFINITY: a multicentre, single-arm, multi-cohort, phase Ⅱ trial of tremelimumab and durvalumab as neoadjuvant treatment of patients with microsatellite instability-high (MSI) resectable gastric or gastroesophageal junction adenocarcinoma (GAC/GEJAC)[J]. J Clin Oncol, 2023, 41(4_suppl): 358. DOI: 10.1200/JCO.2023.41.4_suppl.358.
|
| [5] |
Cheng Y, Wu L, Fang Y, et al. Abstract CT248: trastuzumab deruxtecan (T-DXd) in Chinese patients (pts) with previously treated HER2 mutant non-small cell lung cancer (NSCLC): primary analysis from the phase 2 DESTINY-Lung 05 (DL-05) trial[J]. Cancer Research, 2024, 84(7_Suppl): CT248. DOI: 10.1158/1538-7445.AM2024-CT248.
|
| [6] |
Li S, Liu Z, Liu Y, et al. Efficacy of disitamab vedotin (RC48) plus tislelizumab and S-1 as first-line therapy for HER2-overexpressing advanced stomach or gastroesophageal junc-tion adenocarcinoma: a multicenter, single-arm, phase Ⅱ trial (RCTS)[J]. J Clin Oncol, 2024, 42(16_suppl): 4009. DOI: 10.1200/JCO.2024.42.16_suppl.4009.
|
| [7] |
Peng Z, Liu T, Wei J, et al. Efficacy and safety of a novel anti-HER2 therapeutic antibody RC48 in patients with HER2-overexpressing, locally advanced or metastatic gastric or gastroesophageal junction cancer: a single-arm phase Ⅱ study[J]. Cancer Commun (Lond), 2021, 41(11): 1173-1182. DOI: 10.1002/cac2.12214.
|
| [8] |
中国临床肿瘤学会指南工作委员会. 2024版中国临床肿瘤学会CSCO胃癌诊疗指南[M]. 北京: 人民卫生出版社, 2024.
|
| [9] |
Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer[J]. N Engl J Med, 2006, 355(1): 11-20. DOI: 10.1056/NEJMoa055531.
|
| [10] |
Zhang X, Liang H, Li Z, et al. Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma under-going D2 gastrectomy (RESOLVE): an open-label, superiority and non-inferiority, phase 3 randomised controlled trial[J]. Lancet Oncol, 2021, 22(8): 1081-1092. DOI: 10.1016/S1470-2045(21)00297-7.
|
| [11] |
Stahl M, Walz MK, Riera-Knorrenschild J, et al. Preoperative chemotherapy versus chemoradiotherapy in locally advanced adenocarcinomas of the oesophagogastric junction (POET): Long-term results of a controlled randomised trial[J]. Eur J Cancer, 2017, 81: 183-190. DOI: 10.1016/j.ejca.2017.04.027.
|
| [12] |
van der Woude SO, Hulshof MC, van Laarhoven HW. CROSS and beyond: a clinical perspective on the results of the randomized chemoradiotherapy for oesophageal cancer followed by surgery study[J]. Chin Clin Oncol, 2016, 5(1): 13. DOI: 10.3978/j.issn.2304-3865.2016.02.04.
|
| [13] |
Leong T, Smithers BM, Haustermans K, et al. TOPGEAR: a randomized, phase Ⅲ trial of perioperative ecf chemotherapy with or without preoperative chemoradiation for resectable gastric cancer: interim results from an international, intergroup trial of the AGITG, TROG, EORTC and CCTG[J]. Ann Surg Oncol, 2017, 24(8): 2252-2258. DOI: 10.1245/s10434-017-5830-6.
|
| [14] |
Janjigian YY, Kawazoe A, Bai Y, et al. Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial[J]. Lancet, 2023, 402(10418): 2197-2208. DOI: 10.1016/S0140-6736(23)02033-0.
|
| [15] |
Janjigian YY, Shitara K, Moehler M, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesopha-geal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial[J]. Lancet, 2021, 398(10294): 27-40. DOI: 10.1016/S0140-6736(21)00797-2.
|
| [16] |
Xu J, Jiang H, Pan Y, et al. Sintilimab plus chemotherapy for unresectable gastric or gastroesophageal junction cancer: the ORIENT-16 randomized clinical trial[J]. JAMA, 2023, 330(21): 2064-2074. DOI: 10.1001/jama.2023.19918.
|
| [17] |
Janjigian YY, Al-Batran SE, Wainberg ZA, et al. Pathological complete response (pCR) to 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) with or without durvalumab (D) in resectable gastric and gastroesophageal junction cancer (GC/GEJC): Subgroup analysis by region from the phase 3, randomized, double-blind MATTERHORN study[J]. J Clin Oncol, 2024, 42(3_suppl): LBA246. DOI: 10.1200/JCO.2024.42.3_suppl.LBA246.
|
| [18] |
Li C, Tian Y, Zheng Y, et al. Pathologic response of phase Ⅲ study: perioperative camrelizumab plus rivoceranib and chemotherapy versus chemotherapy for locally advanced gastric cancer (DRAGON IV/CAP 05)[J]. J Clin Oncol, 2025, 43(4): 464-474. DOI: 10.1200/JCO.24.00795.
|
| [19] |
Shitara K, Rha SY, Wyrwicz LS, et al. Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 3 study[J]. Lancet Oncol, 2024, 25(2): 212-224. DOI: 10.1016/S1470-2045(23)00541-7.
|
| [20] |
Sun X, Lyu J, Yang M, et al. Two-year outcomes and biomarker analysis of locally advanced gastric and gastroeso-phageal junction adenocarcinoma after neoadjuvant chemotherapy and immunotherapy from the phase Ⅱ Wuhan UHGI001 Trial[J]. Ann Surg Oncol, 2024, 31(12): 8157-8169. DOI: 10.1245/s10434-024-16041-x.
|
| [21] |
Verschoor YL, van de Haar J, van den Berg JG, et al. Neoadjuvant atezolizumab plus chemotherapy in gastric and gastroesophageal junction adenocarcinoma: the phase 2 PANDA trial[J]. Nat Med, 2024, 30(2): 519-530. DOI: 10.1038/s41591-023-02758-x.
|
| [22] |
Karukonda P, Czito B, Duffy E, et al. Pembrolizumab, radiotherapy, and chemotherapy in neoadjuvant treatment of malignant esophago-gastric diseases (PROCEED): assessment of pathologic response and toxicity in a prospective, phase Ⅱ single-arm trial[J]. J Clin Oncol, 2023, 41, 2(16_suppl): 4062. DOI: 10.1016/j.ijrobp.2023.06.226.
|
| [23] |
Tang Z, Wang Y, Liu D, et al. The neo-PLANET phase Ⅱ trial of neoadjuvant camrelizumab plus concurrent chemoradiotherapy in locally advanced adenocarcinoma of stomach or gastroesophageal junction[J]. Nat Commun, 2022, 13(1): 6807. DOI: 10.1038/s41467-022-34403-5.
|
| [24] |
Wei J, Lu X, Liu Q, et al. SHARED: Efficacy and safety of sintilimab in combination with concurrent chemoradiotherapy (cCRT) in patients with locally advanced gastric (G) or gastroesophageal junction (GEJ) adenocarcinoma[J]. J Clin Oncol, 2021, 39(15_suppl): 4040. DOI: 10.1200/JCO.2021.39.15_suppl.4040.
|
| [25] |
Rha SY, Lee C, Kim HS, et al. A multi-institutional phase Ⅰb/Ⅱ trial of first-line triplet regimen (pembrolizumab, trastuzumab, chemotherapy) for HER2-positive advanced gastric and gastroesophageal junction cancer (PANTHERA Trial): molecular profiling and clinical update[J]. J Clin Oncol, 2021, 39(3_suppl): 218. DOI: 10.1200/JCO.2021.39.3_suppl.218.
|
| [26] |
Zhao C, Meng X, Shan Z, et al. Efficacy and safety of perioperative chemotherapy combined with tislelizumab and trastuzumab for HER2-positive resectable gastric/gastroeso-phageal junction cancer (GC/EGJC): Preliminary results of a phase 2, single-arm trial[J]. J Clin Oncol, 2023, 41(16_suppl): e16084. DOI: 10.1200/JCO.2023.41.16_suppl.e16084.
|
| [27] |
|
| [28] |
Etoh T, Ohyama T, Sakuramoto S, et al. Five-year survival outcomes of laparoscopy-assisted vs open distal gastrectomy for advanced gastric cancer: the JLSSG0901 randomized clinical trial[J]. JAMA Surg, 2023, 158(5): 445-454. DOI: 10.1001/jamasurg.2023.0096.
|
| [29] |
Huang C, Liu H, Hu Y, et al. Laparoscopic vs open distal gastrectomy for locally advanced gastric cancer: five-year outcomes from the CLASS-01 randomized clinical trial[J]. JAMA Surg, 2022, 157(1): 9-17. DOI: 10.1001/jamasurg.2021.5104.
|
| [30] |
Hyung WJ, Yang HK, Park YK, et al. Long-term outcomes of laparoscopic distal gastrectomy for locally advanced gastric cancer: the KLASS-02-RCT randomized clinical trial[J]. J Clin Oncol, 2020, 38(28): 3304-3313. DOI: 10.1200/JCO.20.01210.
|
| [31] |
Du R, Wan Y, Shang Y, et al. Robotic versus laparoscopic gastrectomy for gastric cancer: the largest systematic reviews of 68, 755 patients and meta-analysis[J]. Ann Surg Oncol, 2025, 32(1): 351-373. DOI: 10.1245/s10434-024-16371-w.
|
| [32] |
Lu J, Xu BB, Zheng HL, et al. Robotic versus laparoscopic distal gastrectomy for resectable gastric cancer: a randomized phase 2 trial[J]. Nat Commun, 2024, 15(1): 4668. DOI: 10.1038/s41467-024-49013-6.
|
| [33] |
Kuroda S, Choda Y, Otsuka S, et al. Multicenter retrospective study to evaluate the efficacy and safety of the double-flap technique as antireflux esophagogastrostomy after proximal gastrectomy (rD-FLAP Study)[J]. Ann Gastroenterol Surg, 2019, 3(1): 96-103. DOI: 10.1002/ags3.12216.
|
| [34] |
Kurokawa Y, Takeuchi H, Doki Y, et al. Mapping of lymph node metastasis from esophagogastric junction tumors: a prospective nationwide multicenter study[J]. Ann Surg, 2021, 274(1): 120-127. DOI: 10.1097/SLA.0000000000003499.
|
| [35] |
Takahashi R, Ohashi M, Hiki N, et al. Risk factors and prognosis of gastric stasis, a crucial problem after laparoscopic pylorus-preserving gastrectomy for early middle-third gastric cancer[J]. Gastric Cancer, 2020, 23(4): 707-715. DOI: 10.1007/s10120-019-01037-4.
|
| [36] |
Bang YJ, Kim YW, Yang HK, et al. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial[J]. Lancet, 2012, 379(9813): 315-321. DOI: 10.1016/S0140-6736(11)61873-4.
|
| [37] |
Terashima M, Kang YK, Kim YW, et al. ATTRACTION-5: a phase 3 study of nivolumab plus chemotherapy as postoperative adjuvant treatment for pathological stage Ⅲ (pStage Ⅲ) gastric or gastroesophageal junction (G/GEJ) cancer[J]. J Clin Oncol, 2023, 41(16_suppl): 4000. DOI: 10.1200/JCO.2023.41.16_suppl.4000.
|
| [38] |
Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction[J]. N Engl J Med, 2001, 345(10): 725-730. DOI: 10.1056/NEJMoa010187.
|
| [39] |
Park SH, Lim DH, Sohn TS, et al. A randomized phase Ⅲ trial comparing adjuvant single-agent S1, S-1 with oxaliplatin, and postoperative chemoradiation with S-1 and oxaliplatin in patients with node-positive gastric cancer after D2 resection: the ARTIST 2 trial☆[J]. Ann Oncol, 2021, 32(3): 368-374. DOI: 10.1016/j.annonc.2020.11.017.
|
| [40] |
Park SH, Sohn TS, Lee J, et al. Phase Ⅲ trial to compare adjuvant chemotherapy with capecitabine and cisplatin versus concurrent chemoradiotherapy in gastric cancer: final report of the adjuvant chemoradiotherapy in stomach tumors trial, including survival and subset analyses[J]. J Clin Oncol, 2015, 33(28): 3130-3136. DOI: 10.1200/JCO.2014.58.3930.
|
| [41] |
Peng J, Wei Y, Zhou F, et al. D2-resected stage Ⅲc gastric cancer patients benefit from adjuvant chemoradiotherapy[J]. Cancer Med, 2016, 5(10): 2773-2780. DOI: 10.1002/cam4.873.
|
| [42] |
Fan M, Li G, Shen L, et al. Identification of patients with lymph node metastasis from gastric cancer who may benefit from adjuvant chemoradiotherapy after D2 dissection-do N3 patients benefit from additional radiation?[J]. Br J Radiol, 2016, 89(1059): 20150758. DOI: 10.1259/bjr.20150758.
|
| [43] |
Zhou ML, Yang W, Wang YQ, et al. Adjuvant chemoradiotherapy versus adjuvant chemotherapy for patients with N3 gastric cancer after D2/R0 resection: a retrospective study based on propensity score analyses[J]. Cancer Manag Res, 2019, 11: 4855-4870. DOI: 10.2147/CMAR.S195130.
|
| [44] |
Wang SB, Qi WX, Chen JY, et al. Competing risk nomogram predicting initial loco-regional recurrence in gastric cancer patients after D2 gastrectomy[J]. Radiat Oncol, 2019, 14(1): 128. DOI: 10.1186/s13014-019-1332-y.
|
| [45] |
Zhu ZG, Tang R, Yan M, et al. Efficacy and safety of intraoperative peritoneal hyperthermic chemotherapy for advanced gastric cancer patients with serosal invasion. A long-term follow-up study[J]. Dig Surg, 2006, 23(1/2): 93-102. DOI: 10.1159/000093778.
|
| [46] |
|
| [47] |
Azad TD, Chaudhuri AA, Fang P, et al. Circulating tumor DNA analysis for detection of minimal residual disease after chemoradiotherapy for localized esophageal cancer[J]. Gastroenterology, 2020, 158(3): 494-505.e6. DOI: 10.1053/j.gastro.2019.10.039.
|
| [48] |
Scherer F, Kurtz DM, Newman AM, et al. Distinct biological subtypes and patterns of genome evolution in lympho-ma revealed by circulating tumor DNA[J]. Sci Transl Med, 2016, 8(364): 364ra155. DOI: 10.1126/scitranslmed.aai8545.
|
| [49] |
Tan L, Sandhu S, Lee RJ, et al. Prediction and monitoring of relapse in stage Ⅲ melanoma using circulating tumor DNA[J]. Ann Oncol, 2019, 30(5): 804-814. DOI: 10.1093/annonc/mdz048.
|
| [50] |
Tie J, Wang Y, Tomasetti C, et al. Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage Ⅱ colon cancer[J]. Sci Transl Med, 2016, 8(346): 346ra92. DOI: 10.1126/scitranslmed.aaf6219.
|
| [51] |
Huffman BM, Aushev VN, Budde GL, et al. Analysis of circulating tumor dna to predict risk of recurrence in patients with esophageal and gastric cancers[J]. JCO Precis Oncol, 2022, 6: e2200420. DOI: 10.1200/PO.22.00420.
|
| [52] |
Maron SB, Chase LM, Lomnicki S, et al. Circulating tumor DNA sequencing analysis of gastroesophageal adenocarcinoma[J]. Clin Cancer Res, 2019, 25(23): 7098-7112. DOI: 10.1158/1078-0432.CCR-19-1704.
|
| [53] |
Yang J, Gong Y, Lam VK, et al. Deep sequencing of circulating tumor DNA detects molecular residual disease and predicts recurrence in gastric cancer[J]. Cell Death Dis, 2020, 11(5): 346. DOI: 10.1038/s41419-020-2531-z.
|
| [54] |
Al-Batran SE, Goetze TO, Mueller DW, et al. The RENAISSANCE (AIO-FLOT5) trial: effect of chemotherapy alone vs. chemotherapy followed by surgical resection on survival and quality of life in patients with limited-metastatic adenocarcinoma of the stomach or esophagogastric junction-a phase Ⅲ trial of the German AIO/CAO-V/CAOGI[J]. BMC Cancer, 2017, 17(1): 893. DOI: 10.1186/s12885-017-3918-9.
|
| [55] |
Chevallay M, Wassmer CH, Iranmanesh P, et al. Multimodal treatment in oligometastatic gastric cancer[J]. World J Gastrointest Oncol, 2022, 14(2): 434-449. DOI: 10.4251/wjgo.v14.i2.434.
|
| [56] |
Sawasaki M, Tsubamoto H, Nakamoto Y, et al. S-1, oxaliplatin, nab-paclitaxel and itraconazole for conversion surgery for advanced or recurrent gastric cancer[J]. Anticancer Res, 2020, 40(2): 991-997. DOI: 10.21873/anticanres.14033.
|
| [57] |
Yoshida K, Yasufuku I, Terashima M, et al. International retrospective cohort study of conversion therapy for stage Ⅳ gastric cancer 1 (CONVO-GC-1)[J]. Ann Gastroenterol Surg, 2022, 6(2): 227-240. DOI: 10.1002/ags3.12515.
|
| [58] |
Oyama K, Fushida S, Kinoshita J, et al. Efficacy of pre-operative chemotherapy with docetaxel, cisplatin, and S-1 (DCS therapy) and curative resection for gastric cancer with pathologically positive para-aortic lymph nodes[J]. J Surg Oncol, 2012, 105(6): 535-541. DOI: 10.1002/jso.22125.
|
| [59] |
Al-Batran SE, Lorenzen S, Riera J, et al. Effect of chemotherapy/targeted therapy alone vs. chemotherapy/targeted therapy followed by radical surgical resection on survival and quality of life in patients with limited-metastatic adenocarcinoma of the stomach or esophagogastric junction: the IKF-575/RENAISSANCE phase Ⅲ trial[J]. J Clin Oncol, 2024, 42(17_suppl): LBA4001. DOI: 10.1200/JCO.2024.42.17_suppl.LBA4001.
|
| [60] |
Li S, Yu W, Xie F, et al. Neoadjuvant therapy with immune checkpoint blockade, antiangiogenesis, and chemotherapy for locally advanced gastric cancer[J]. Nat Commun, 2023, 14(1): 8. DOI: 10.1038/s41467-022-35431-x.
|
| [61] |
Xue Q, Wang B, Wang X, et al. CO-STAR: Surgical conversion feasibility trial of sintilimab (PD-1 inhibitor) combined with Nab-PTX, S-1 and apatinib for the first-line treatment of stage Ⅳ gastric cancer (GC)[J]. J Clin Oncol, 2021, 39(15_suppl): e16041. DOI: 10.1200/JCO.2021.39.15_suppl.e16041.
|
| [62] |
Liang H, Yan X, Li Z, et al. Clinical outcomes of conversion surgery following immune checkpoint inhibitors and chemotherapy in stage Ⅳ gastric cancer[J]. Int J Surg, 2023, 109(12): 4162-4172. DOI: 10.1097/JS9.0000000000000738.
|
| [63] |
Bonnot PE, Piessen G, Kepenekian V, et al. Cytoreductive surgery with or without hyperthermic intraperitoneal che-motherapy for gastric cancer with peritoneal metastases (CYTO-CHIP study): a propensity score analysis[J]. J Clin Oncol, 2019, 37(23): 2028-2040. DOI: 10.1200/JCO.18.01688.
|
| [64] |
Rau B, Lang H, Koenigsrainer A, et al. Effect of hyperthermic intraperitoneal chemotherapy on cytoreductive surgery in gastric cancer with synchronous peritoneal metastases: the phase Ⅲ GASTRIPEC-I trial[J]. J Clin Oncol, 2024, 42(2): 146-156. DOI: 10.1200/JCO.22.02867.
|
| [65] |
Kroese TE, Jorritsma NKN, van Laarhoven HWM, et al. Stereotactic radiotherapy or metastasectomy for oligometastatic esophagogastric cancer: a nationwide population-based cohort study[J]. Clin Transl Radiat Oncol, 2022, 37: 109-115. DOI: 10.1016/j.ctro.2022.08.012.
|
| [66] |
Matoska T, Banerjee A, Shreenivas A, et al. Definitive chemoradiation associated with improved survival outcomes in patients with synchronous oligometastatic esophageal cancer[J]. Cancers (Basel), 2023, 15(9): 2523. DOI: 10.3390/cancers15092523.
|
| [67] |
Mizrak Kaya D, Wang X, Harada K, et al. 101 long-term survivors who had metastatic gastroesophageal cancer and received local consolidative therapy[J]. Oncology, 2017, 93(4): 243-248. DOI: 10.1159/000475550.
|
| [68] |
Palma DA, Olson R, Harrow S, et al. Stereotactic ablative radiotherapy for the comprehensive treatment of oligometastatic cancers: long-term results of the SABR-COMET phase Ⅱ Randomized Trial[J]. J Clin Oncol, 2020, 38(25): 2830-2838. DOI: 10.1200/JCO.20.00818.
|
| [69] |
Xu RH, Zhang Y, Pan H, et al. Efficacy and safety of weekly paclitaxel with or without ramucirumab as second-line therapy for the treatment of advanced gastric or gastroesophageal junction adenocarcinoma (RAINBOW-Asia): a randomised, multicentre, double-blind, phase 3 trial[J]. Lancet Gastroenterol Hepatol, 2021, 6(12): 1015-1024. DOI: 10.1016/S2468-1253(21)00313-7.
|
| [70] |
Wang F, Shen L, Guo W, et al. Fruquintinib plus paclitaxel versus placebo plus paclitaxel for gastric or gastroesophageal junction adenocarcinoma: the randomized phase 3 FRUTIGA trial[J]. Nat Med, 2024, 30(8): 2189-2198. DOI: 10.1038/s41591-024-02989-6.
|
| [71] |
Dai G, Wang Y, Jia R, et al. 1416P First-line tislelizumab combined with bevacizumab and CAPOX for metastatic gastroesophageal adenocarcinoma (mGEA) with PD-L1 CPS < 5: updated results of a phase Ⅱ, prospective, single-arm study[J]. Ann Oncol, 2024, 35(2_suppl): S884. DOI: 10.1016/j.annonc.2024.08.1482.
|
| [72] |
Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial[J]. Lancet, 2010, 376(9742): 687-697. DOI: 10.1016/S0140-6736(10)61121-X.
|
| [73] |
Catenacci DVT, Kang YK, Saeed A, et al. FIGHT: a randomized, double-blind, placebo-controlled, phase Ⅱ study of bemarituzumab (bema) combined with modified FOLFOX6 in 1L FGFR2b+advanced gastric/gastroesophageal junction adenocarcinoma (GC)[J]. J Clin Oncol, 2021, 39(15_suppl): 4010. DOI: 10.1200/JCO.2021.39.15_suppl.4010.
|
| [74] |
Kang YK, Qin S, Lee KW, et al. Bemarituzumab plus mFOLFOX6 as first-line treatment in East Asian patients with FGFR2b-overexpressing locally advanced or metastatic gastric/gastroesophageal junction cancer: subgroup of FIGHT final analysis[J]. Gastric Cancer, 2024, 27(5): 1046-1057. DOI: 10.1007/s10120-024-01516-3.
|
| [75] |
Shitara K, Lordick F, Bang YJ, et al. Zolbetuximab+mFOLFOX6 as first-line (1L) treatment for patients (pts) withclaudin-18.2+(CLDN18.2+)/HER2-locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma: primary results from phase 3 SPOTLIGHT study[J]. J Clin Oncol, 2023, 41(4_suppl): LBA292. DOI: 10.1200/JCO.2023.41.4_suppl.LBA292.
|
| [76] |
Lordick F, Shah MA, Shitara K, et al. LBA81 Updated efficacy and safety results from phase Ⅲ GLOW study evaluating zolbetuximab+CAPOX as first-line (1L) treatment for patients with claudin-18 isoform 2-positive (CLDN18.2+), HER2-, locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocar[J]. Ann Oncol, 2023, 34(2_suppl): S1321. DOI: 10.1016/j.annonc.2023.10.082.
|
| [77] |
Shah MA, Shitara K, Ajani JA, et al. Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial[J]. Nat Med, 2023, 29(8): 2133-2141. DOI: 10.1038/s41591-023-02465-7.
|
| [78] |
QI C, Liu C, Gong J, et al. Claudin18.2-targeted chimeric antigen receptor T cell-therapy for patients with gastrointestinal cancers: final results of CT041-CG4006 phase 1 trial[J]. J Clin Oncol, 2024, 42(16_suppl): 2501. DOI: 10.1200/JCO.2024.42.16_suppl.2501.
|
| [79] |
Zhang X, Guo Z, Zhang J, et al. First-line osemitamab (TST001) plus nivolumab and capox for advanced g/GEJ cancer (TranStar102): results of cohort G from a phase Ⅰ/Ⅱa study[J]. J Clin Oncol, 2024, 42(16_suppl): 4048. DOI: 10.1200/JCO.2024.42.16_suppl.4048.
|
| [80] |
Metzger ML, Behrens HM, Böger C, et al. MET in gastric cancer-discarding a 10% cutoff rule[J]. Histopathology, 2016, 68(2): 241-253. DOI: 10.1111/his.12745.
|
| [81] |
Lee J, Kim ST, Kim K, et al. Tumor genomic profiling guides patients with metastatic gastric cancer to targeted treatment: the VIKTORY umbrella trial[J]. Cancer Discov, 2019, 9(10): 1388-1405. DOI: 10.1158/2159-8290.CD-19-0442.
|
| [82] |
Peng Z, Wang H, Liu B, et al. Abstract CT152: a multicenter Phase Ⅱ study of savolitinib in patients with MET-amplified gastroesophogeal junction adenocarcinomas or gastric cancer[J]. Cancer Res, 2023, 83(8_Suppl): CT152. DOI: 10.1158/1538-7445.AM2023-CT152.
|
| [83] |
Janjigian YY, Bendell J, Calvo E, et al. CheckMate-032 study: efficacy and safety of nivolumab and nivolumab plus ipilimumab in patients with metastatic esophagogastric cancer[J]. J Clin Oncol, 2018, 36(28): 2836-2844. DOI: 10.1200/JCO.2017.76.6212.
|
| [84] |
Zhang X, Wang Y, Xiang X, et al. Efficacy and safety of cadonilimab in combination with pulocimab and paclitaxel as second-line therapy in patients with advanced gastric or gastroesophageal junction (G/GEJ) cancer who failed immunochemotherapy: a multicenter, double-blind, randomized trial[J]. J Clin Oncol, 2024, 42(16_suppl): 4012. DOI: 10.1200/JCO.2024.42.16_suppl.401.
|
| [85] |
Peng Z, Wang J, Zhang Y, et al. LBA60 Phase Ⅲ study of SHR-1701 versus placebo in combination with chemo as first-line (1L) therapy for HER2-negative gastric/gastroesophageal junction adenocarcinoma (G/GEJA)[J]. Ann Oncol, 2024, 35: S1250. DOI: 10.1016/j.annonc.2024.08.2302.
|
DownLoad: